CNTX Context Therapeutics Inc.
Context Therapeutics Inc. (CNTX) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.8% since its last earnings release on November 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Context Therapeutics Inc.
Context Therapeutics Inc. is a biopharmaceutical company committed to advancing medicines for solid tumors.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.